Evidence map›Paper›PMID 36629012›Full record

ArticleEMBO reports2023

BTNL2 promotes colitis-associated tumorigenesis in mice by regulating IL-22 production.

Qianwen Peng, Ting Pan, Ruirui He, Ming Yi, Lingyun Feng, Zhihui Cui, Ru Gao, Heping Wang, Xiong Feng, Hui Li and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer.International journal of molecular sciences · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Qianwen Peng *Key Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Ting Pan *Key Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Ruirui HeThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.
Ming YiThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.
Lingyun FengThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.
Zhihui CuiKey Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0001-7970-4585
Ru GaoKey Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Heping WangKey Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-8357-0222
Xiong FengKey Laboratory of Molecular Biophysics of the Ministry of Education, National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Hui LiShandong Polytechnic, Jinan, China.
Yuan WangThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.
Cun-Jin ZhangDepartment of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Du ChengDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.ORCID 0000-0002-6026-0520
Yanyun DuThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.
Chenhui WangThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People's Hospital, Medical School, University of Electronic Science and Technology of China, Chengdu, China.ORCID 0000-0002-3186-3066
University of Electronic Science and Technology of China · CNHuazhong University of Science and Technology · CNNanjing Drum Tower Hospital · CNShandong Police College · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin 22 (IL-22) has an important role in colorectal tumorigenesis and many colorectal diseases such as inflammatory bowel disease and certain infections. However, the regulation of IL-22 production in the intestinal system is still unclear. Here, we present evidence that butyrophilin-like protein 2 (BTNL2) is required for colorectal IL-22 production, and BTNL2 knockout mice show decreased colonic tumorigenesis and more severe colitis phenotypes than control mice due to defective production of IL-22. Mechanistically, BTNL2 acts on group 3 innate lymphoid cells (ILC3s), CD4

Indexed as

ColitisColorectal NeoplasmsAnimalsButyrophilinsCarcinogenesisCell Transformation, NeoplasticDisease Models, AnimalHumansImmunity, InnateInterleukin-22LymphocytesMiceMice, Inbred C57BLMice, KnockoutBTNL2 protein, humanBTNL2 protein, mouseButyrophilinsInterleukin-22BTNL2colitiscolorectal cancerIL-22

Identifiers

PMID36629012
PMCPMC9986825
OpenAlexW4315620185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.